Amidopyridinol derivative or pharmaceutically acceptable salt thereof and pharmaceutical composition comprising same as active component

A method of treating an inflammatory bowel disease in a subject in need thereof, comprising:

• administering an effective amount of a compound represented by Chemical Formula 2 or a pharmaceutically acceptable salt thereof to the subject,
• wherein, in Chemical Formula 2 above,
• R1, R2, and R4 are identical to or different from each other, and are each independently one selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, and halogen,
• R3 is one selected from C1-C4 alkoxy, benzyloxy, and hydroxyl, and,
• R5 is one selected from C1-C15 alkyl substituted or not substituted with one or two substituents selected from halogen, hydroxy, C1-C12 alkoxy, phenoxy, C1-C12 alkylamino, C6-C14aryl, and C1-C4 alkyl;
• C6-C14 aryl substituted or not substituted with one or two substituents selected from halogen, hydroxy, C1-C12 alkoxy, C1-C12 alkylamino, and C1-C4alkyl;
• C2-C12 alkenyl substituted or not substituted with C6-C14 aryl;
• C3-C8 cycloalkyl;
• a 5- to 6-membered monocyclic heterocyclic compound containing one or two heteroatoms selected from N, S or O;
• a heterocyclic compound containing a double ring structure having the 5- to 6-membered monocyclic heterocyclic compound and a phenyl;
• and naphthalene.

A method of treating a lung or breast cancer in a subject in need thereof, comprising:

• administering an effective amount of a compound represented by Chemical Formula 2 or a pharmaceutically acceptable salt thereof to the subject,
• wherein, in Chemical Formula 2 above,
• R1, R2, and R4 are identical to or different from each other, and are each independently one selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, and halogen,
• R3 is one selected from C1-C4 alkoxy, benzyloxy, and hydroxyl, and
• R5 is one selected from C1-C15 alkyl substituted or not substituted with one or two substituents selected from halogen, hydroxy, C1-C12 alkoxy, phenoxy, C1-C12 alkylamino, C6-C14 aryl, and C1-C4 alkyl;
• C6-C14 aryl substituted or not substituted with one or two substituents selected from halogen, hydroxy, C1-C12 alkoxy, C1-C12 alkylamino, and C1-C4 alkyl;
• C2-C12 alkenyl substituted or not substituted with C6-C14 aryl;
• C3-C8 cycloalkyl;
• a 5- to 6-membered monocyclic heterocyclic compound containing one or two heteroatoms selected from N, S or O;
• a heterocyclic compound containing a double ring structure having the 5- to 6- membered monocyclic heterocyclic compound and a phenyl;
• and naphthalene,
• wherein the compound inhibits invasion of cancer or metastasis.